The DOI matches its Crossref record.
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
Abstract
PURPOSE: To retrospectively construct a comprehensive multivariate model of cancer recurrence and to design a molecular pathologic substaging system in stage I non-small-cell lung cancer (NSCLC). METHODS: All patients with stage I NSCLC resected at Brigham and Women's Hospital (Boston, MA) between 1984 and 1992 with adequate clinical follow-up were studied. The importance of three demographic characteristics, surgical extent, 11 pathologic features, and seven molecular factors on cancer-free survival was examined. RESULTS: Two hundred forty-four patients were studied, with 25 noncancer deaths and 80 patients with recurrent disease. Significant univariate predictors (P < .05) of cancer recurrence were age older than 60 years, male sex, wedge resection, World Health Organization (WHO) adenocarcinoma subtype solid tumor with mucin, lymphatic invasion, and p53 expression. Multivariate analysis identified nine independent predictors of recurrence: solid tumor with mucin, a wedge resection, tumor diameter of 4 cm or greater, lymphatic invasion, age older than 60 years, male sex, p53 expression, K-ras codon 12 mutation, and absence of H-ras p21 expression. Multivariate cancer-free survival (CFS) analysis in the 180 patients who underwent lobectomy or pneumonectomy led to the elimination of sex and age, which left six independent factors. CONCLUSION: Lobectomy or pneumonectomy should be performed in stage I NSCLC. Using the six independent factors for recurrent disease, we propose a pathologic molecular substaging system. Patients with two factors or less are graded Ia, with a 5-year CFS rate of 87%; those with three factors are graded Ib, with a 5-year CFS rate of 58%; and those with four factors or more are graded Ic, with a 5-year CFS rate of 21%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
Steels, E., Paesmans, M., Berghmans, T., Branle, F., Lemaitre, F., Mascaux, C., Meert, A. P., Vallot, F., Lafitte, J. J., & Sculier, J. P. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00062201 · Cited by 418
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
Cerfolio, R. J., Bryant, A. S., Ohja, B., & Bartolucci, A. A. (2005) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.11.007 · Cited by 317
Tang, X. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1511 · Cited by 314
Metadata
- Authors
- Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-07
- Volume
- 16
- Issue
- 7
- Pages
- 2468-2477
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2148725505
- Cited by
- 178
- References
- 0
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. https://app.cochat.ai/papers/10.1200/jco.1998.16.7.2468
- The paper
- Kwiatkowski, D. J., Harpole, D. H., Godleski, J., Herndon, J. E., Shieh, D. B., Richards, W., Blanco, R., Xu, H. J., Strauss, G. M., & Sugarbaker, D. J. (1998). Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.7.2468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.